Combining two complementary methods, we identified 22 candidate proteins with prognostic potential in ALK fusion positive NSCLC treated with crizotinib, 3 of which (DPP4, LUM and KIT) were consistently identified in all comparisons and analyses performed. The gene discussed is ALK; the disease is non-small cell lung carcinoma.